CN108610312A - 具有改善的治疗指数的硝酰基供体 - Google Patents

具有改善的治疗指数的硝酰基供体 Download PDF

Info

Publication number
CN108610312A
CN108610312A CN201810074807.8A CN201810074807A CN108610312A CN 108610312 A CN108610312 A CN 108610312A CN 201810074807 A CN201810074807 A CN 201810074807A CN 108610312 A CN108610312 A CN 108610312A
Authority
CN
China
Prior art keywords
compound
alkyl
pharmaceutical composition
nitroxyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810074807.8A
Other languages
English (en)
Chinese (zh)
Inventor
文森·杰可·卡利什
费德列克·阿瑟·布鲁克菲尔德
史蒂芬·马汀·考特尼
莉萨·玛莉·弗罗斯特
约翰·P·托斯卡诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardioxyl Pharmaceuticals Inc
Original Assignee
Cardioxyl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardioxyl Pharmaceuticals Inc filed Critical Cardioxyl Pharmaceuticals Inc
Publication of CN108610312A publication Critical patent/CN108610312A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201810074807.8A 2013-01-18 2014-01-17 具有改善的治疗指数的硝酰基供体 Pending CN108610312A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361754237P 2013-01-18 2013-01-18
US61/754,237 2013-01-18
US201361782781P 2013-03-14 2013-03-14
US61/782,781 2013-03-14
CN201480013565.1A CN105073105B (zh) 2013-01-18 2014-01-17 具有改善的治疗指数的硝酰基供体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480013565.1A Division CN105073105B (zh) 2013-01-18 2014-01-17 具有改善的治疗指数的硝酰基供体

Publications (1)

Publication Number Publication Date
CN108610312A true CN108610312A (zh) 2018-10-02

Family

ID=50064795

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201810074807.8A Pending CN108610312A (zh) 2013-01-18 2014-01-17 具有改善的治疗指数的硝酰基供体
CN201480013565.1A Active CN105073105B (zh) 2013-01-18 2014-01-17 具有改善的治疗指数的硝酰基供体
CN201910446030.8A Active CN110179777B (zh) 2013-01-18 2014-01-17 包含硝酰基供体的医药组合物
CN201480013223.XA Active CN105142627B (zh) 2013-01-18 2014-01-17 包含硝酰基供体的医药组合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201480013565.1A Active CN105073105B (zh) 2013-01-18 2014-01-17 具有改善的治疗指数的硝酰基供体
CN201910446030.8A Active CN110179777B (zh) 2013-01-18 2014-01-17 包含硝酰基供体的医药组合物
CN201480013223.XA Active CN105142627B (zh) 2013-01-18 2014-01-17 包含硝酰基供体的医药组合物

Country Status (29)

Country Link
US (13) US10245249B2 (enExample)
EP (5) EP3567031A1 (enExample)
JP (5) JP6449171B2 (enExample)
KR (2) KR102277165B1 (enExample)
CN (4) CN108610312A (enExample)
AU (5) AU2014207408C1 (enExample)
BR (2) BR112015017251B1 (enExample)
CA (2) CA2898443C (enExample)
CY (3) CY1120535T1 (enExample)
DK (3) DK2945620T3 (enExample)
ES (4) ES2751922T3 (enExample)
HK (1) HK1251170B (enExample)
HR (3) HRP20180121T1 (enExample)
HU (3) HUE046722T2 (enExample)
IL (4) IL239906B (enExample)
LT (3) LT3284463T (enExample)
MX (2) MX363843B (enExample)
NZ (4) NZ709986A (enExample)
PL (3) PL2945621T3 (enExample)
PT (3) PT3284463T (enExample)
RS (3) RS56968B1 (enExample)
RU (3) RU2684916C2 (enExample)
SG (6) SG10201802855TA (enExample)
SI (3) SI3284463T1 (enExample)
SM (3) SMT201800088T1 (enExample)
TR (1) TR201802211T4 (enExample)
TW (3) TWI712409B (enExample)
WO (2) WO2014113700A1 (enExample)
ZA (2) ZA201505090B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811258T3 (es) 2006-03-17 2021-03-11 Univ Johns Hopkins Derivados de N-hidroxilsulfonamida como nuevos donantes de nitroxilo fisiológicamente útiles
BR112014009282B1 (pt) 2011-10-17 2021-12-14 The Johns Hopkins University Composto, composição farmacêutica contendo-o e uso do mesmo
US10245249B2 (en) 2013-01-18 2019-04-02 Cardioxyl Pharmaceuticals, Inc. Pharmaceutical compositions comprising nitroxyl donors
WO2015109210A1 (en) 2014-01-17 2015-07-23 Cardioxyl Pharmaceuticals, Inc. N-hydroxymethanesulfonamide nitroxyl donors
EP3148972B1 (en) 2014-05-27 2019-08-21 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
WO2017041701A1 (zh) 2015-09-07 2017-03-16 浙江华海药业股份有限公司 可释放一氧化氮的前药分子
US10723704B2 (en) 2015-10-19 2020-07-28 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
CN108368038A (zh) 2015-10-19 2018-08-03 卡尔迪奥克斯尔制药公司 作为硝酰基供体的n-羟基磺酰胺衍生物
JP7194436B2 (ja) 2016-07-28 2022-12-22 ザ ジョンズ ホプキンス ユニバーシティ Ｏ－置換ヒドロキサム酸
BR112019013702A2 (pt) 2017-01-03 2020-03-03 Cardioxyl Pharmaceuticals, Inc. Método de administração de compostos doadores de nitroxila
MX2019012535A (es) * 2017-04-18 2020-08-17 Genfit Combinacion que comprende un agonista de ppar tal como elafibranor y un inhibidor de la acetil-coa carboxilasa (acc).
CN116283762B (zh) * 2023-03-28 2025-08-12 昆山市第一人民医院 一种用于制备白鲜碱的中间体化合物及其制备方法、白鲜碱的制备方法
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1143950A (zh) * 1994-01-19 1997-02-26 比克荷兰有限公司 含硝酰基的苄胺衍生物及其在治疗心血管疾病和治疗升高眼压中的应用
CN101874018A (zh) * 2007-09-26 2010-10-27 约翰斯霍普金斯大学 作为新的在生理学上可用于硝酰基供体的n-羟基磺酰胺衍生物
CN102076342A (zh) * 2008-05-07 2011-05-25 卡尔迪奥克斯尔制药公司 作为硝酰基供体的新亚硝基化合物及其使用方法
CN102753520A (zh) * 2009-12-07 2012-10-24 约翰斯霍普金斯大学 N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物
CN102753519A (zh) * 2009-12-07 2012-10-24 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US1021340A (en) 1911-10-14 1912-03-26 William A Scott Means for attaching binding-posts to dry batteries.
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
EP0188040B1 (en) 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0828240B2 (ja) 1990-05-25 1996-03-21 矢崎総業株式会社 電線相互の圧着接続構造及び圧着接続方法
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
JPH10142729A (ja) 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
AU741180B2 (en) 1997-10-24 2001-11-22 Shionogi & Co., Ltd. Antirheumatic
DE69906397T2 (de) 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
AU4333799A (en) 1998-06-04 1999-12-20 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
KR100501022B1 (ko) 1998-07-28 2005-07-18 다나베 세이야꾸 가부시키가이샤 장내 적소 방출형 제제
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
HUP0303857A3 (en) * 2000-12-13 2007-07-30 Wyeth Corp Heterocyclic sulifonamide inhibitors of beta amyloid production
EP1219306A1 (en) 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20050250737A1 (en) 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
AU2005209843B2 (en) 2004-01-30 2012-02-16 The Johns Hopkins University Nitroxyl progenitor compounds and methods of use
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
WO2007002444A1 (en) 2005-06-23 2007-01-04 Johns Hopkins University Thiol-sensitive positive inotropes
ES2811258T3 (es) 2006-03-17 2021-03-11 Univ Johns Hopkins Derivados de N-hidroxilsulfonamida como nuevos donantes de nitroxilo fisiológicamente útiles
US7696373B2 (en) 2006-04-13 2010-04-13 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
US20110160200A1 (en) 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
BR112014009282B1 (pt) 2011-10-17 2021-12-14 The Johns Hopkins University Composto, composição farmacêutica contendo-o e uso do mesmo
US9676708B2 (en) 2012-11-01 2017-06-13 The Johns Hopkins University Controlled HNO release through intramolecular cyclization-elimination
US10245249B2 (en) 2013-01-18 2019-04-02 Cardioxyl Pharmaceuticals, Inc. Pharmaceutical compositions comprising nitroxyl donors
WO2015109210A1 (en) 2014-01-17 2015-07-23 Cardioxyl Pharmaceuticals, Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1143950A (zh) * 1994-01-19 1997-02-26 比克荷兰有限公司 含硝酰基的苄胺衍生物及其在治疗心血管疾病和治疗升高眼压中的应用
CN101874018A (zh) * 2007-09-26 2010-10-27 约翰斯霍普金斯大学 作为新的在生理学上可用于硝酰基供体的n-羟基磺酰胺衍生物
CN102076342A (zh) * 2008-05-07 2011-05-25 卡尔迪奥克斯尔制药公司 作为硝酰基供体的新亚硝基化合物及其使用方法
CN102753520A (zh) * 2009-12-07 2012-10-24 约翰斯霍普金斯大学 N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物
CN102753519A (zh) * 2009-12-07 2012-10-24 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物

Also Published As

Publication number Publication date
DK2945620T3 (en) 2018-02-05
AU2018203240B2 (en) 2019-12-12
AU2014207408B2 (en) 2018-03-01
US20220193026A1 (en) 2022-06-23
JP2019089764A (ja) 2019-06-13
RU2684916C2 (ru) 2019-04-16
AU2014207408C1 (en) 2018-09-06
IL239906B (en) 2018-05-31
US20240066002A1 (en) 2024-02-29
SG11201505567RA (en) 2015-09-29
EP2945621A1 (en) 2015-11-25
EP2945621B1 (en) 2018-10-17
HUE046722T2 (hu) 2020-03-30
PT3284463T (pt) 2019-10-30
NZ709986A (en) 2020-01-31
SG10201802855TA (en) 2018-05-30
US10517847B2 (en) 2019-12-31
CN105073105A (zh) 2015-11-18
JP6801045B2 (ja) 2020-12-16
IL239952A0 (en) 2015-08-31
BR112015017251A2 (pt) 2017-07-11
AU2017200147B2 (en) 2018-07-05
HRP20182144T1 (hr) 2019-03-08
HK1216857A1 (en) 2016-12-09
KR20150107853A (ko) 2015-09-23
TW201442702A (zh) 2014-11-16
HRP20191919T1 (hr) 2020-01-10
DK3284463T3 (da) 2019-10-28
CA2898443A1 (en) 2014-07-24
RU2018143994A (ru) 2019-01-16
CN110179777B (zh) 2022-07-15
KR102277165B1 (ko) 2021-07-14
KR102177899B1 (ko) 2020-11-12
CN110179777A (zh) 2019-08-30
US10548872B2 (en) 2020-02-04
AU2018203240A1 (en) 2018-05-31
SG10201913286PA (en) 2020-02-27
LT3284463T (lt) 2019-11-11
US20180235927A1 (en) 2018-08-23
CN105142627A (zh) 2015-12-09
PL3284463T3 (pl) 2019-12-31
CN105142627B (zh) 2019-06-21
SI3284463T1 (sl) 2019-12-31
SMT201800088T1 (it) 2018-03-08
IL258882A (en) 2018-06-28
TWI686193B (zh) 2020-03-01
PL2945621T3 (pl) 2019-05-31
NZ709985A (en) 2020-05-29
CA2898445C (en) 2022-05-03
SG10201802862WA (en) 2018-05-30
TWI619491B (zh) 2018-04-01
US12186301B2 (en) 2025-01-07
SI2945620T1 (en) 2018-01-31
NZ748771A (en) 2019-12-20
TWI712409B (zh) 2020-12-11
JP6533159B2 (ja) 2019-06-19
EP3427728B1 (en) 2021-07-07
CY1122177T1 (el) 2020-11-25
US20210015784A1 (en) 2021-01-21
HRP20180121T1 (hr) 2018-02-23
US20190133990A1 (en) 2019-05-09
IL259233B (en) 2019-10-31
HK1216858A1 (en) 2016-12-09
TR201802211T4 (tr) 2018-03-21
EP2945620A1 (en) 2015-11-25
SG10201913441RA (en) 2020-03-30
WO2014113696A1 (en) 2014-07-24
BR112015017241B1 (pt) 2021-10-26
MX373176B (es) 2020-04-22
HUE041861T2 (hu) 2019-06-28
CA2898443C (en) 2022-05-31
RU2015134581A (ru) 2017-02-27
US11304924B2 (en) 2022-04-19
ES2705240T3 (es) 2019-03-22
EP2945620B1 (en) 2017-11-22
JP2019172682A (ja) 2019-10-10
US20190224159A1 (en) 2019-07-25
KR20150108879A (ko) 2015-09-30
US10792273B2 (en) 2020-10-06
BR112015017241A8 (pt) 2019-10-29
EP3284463B1 (en) 2019-07-24
SMT201900027T1 (it) 2019-02-28
JP2017125015A (ja) 2017-07-20
AU2018241168A1 (en) 2018-11-01
AU2017200147A1 (en) 2017-02-02
CY1120535T1 (el) 2019-07-10
RS59434B1 (sr) 2019-11-29
JP2016505044A (ja) 2016-02-18
BR112015017251A8 (pt) 2019-10-29
TW201446242A (zh) 2014-12-16
AU2014207408A8 (en) 2015-08-27
US11273143B2 (en) 2022-03-15
US10245249B2 (en) 2019-04-02
LT2945621T (lt) 2019-01-10
RS58174B1 (sr) 2019-03-29
AU2018241168B2 (en) 2020-04-02
EP3567031A1 (en) 2019-11-13
RS56968B1 (sr) 2018-05-31
SG11201505568PA (en) 2015-09-29
US20200121633A1 (en) 2020-04-23
ES2882279T3 (es) 2021-12-01
DK2945621T3 (en) 2019-02-11
EP3427728A1 (en) 2019-01-16
ES2751922T3 (es) 2020-04-02
MX2015009276A (es) 2015-10-30
HUE036589T2 (hu) 2018-07-30
CA2898445A1 (en) 2014-07-24
US20200163929A1 (en) 2020-05-28
US20170151210A1 (en) 2017-06-01
US9968584B2 (en) 2018-05-15
ES2659969T3 (es) 2018-03-20
IL259233A (en) 2018-07-31
US9156804B2 (en) 2015-10-13
WO2014113700A1 (en) 2014-07-24
JP2016510326A (ja) 2016-04-07
JP6656345B2 (ja) 2020-03-04
MX363843B (es) 2019-04-05
SI2945621T1 (sl) 2019-01-31
AU2014207404A1 (en) 2015-08-13
RU2676277C2 (ru) 2018-12-27
PT2945621T (pt) 2019-01-21
NZ748769A (en) 2020-05-29
AU2014207408A1 (en) 2015-08-13
BR112015017241A2 (pt) 2017-07-11
US20150366977A1 (en) 2015-12-24
US20160031807A1 (en) 2016-02-04
WO2014113700A9 (en) 2014-10-09
US8987326B2 (en) 2015-03-24
JP6449171B2 (ja) 2019-01-09
PT2945620T (pt) 2018-02-21
SMT201900575T1 (it) 2019-11-13
US10213408B2 (en) 2019-02-26
JP6311038B2 (ja) 2018-04-11
BR112015017251B1 (pt) 2021-10-26
TW201934120A (zh) 2019-09-01
US20150175566A1 (en) 2015-06-25
MX2015009269A (es) 2015-10-30
US11786501B2 (en) 2023-10-17
PL2945620T3 (pl) 2018-03-30
ZA201505090B (en) 2016-10-26
LT2945620T (lt) 2018-02-12
CY1121480T1 (el) 2020-05-29
CN105073105B (zh) 2018-02-27
EP3284463A1 (en) 2018-02-21
HRP20191919T8 (hr) 2021-10-01
HK1251170B (en) 2020-04-09
AU2014207404B2 (en) 2017-10-19
US20140206769A1 (en) 2014-07-24
RU2015134583A (ru) 2017-02-22
IL239906A0 (en) 2015-08-31
IL239952B (en) 2018-05-31
ZA201604798B (en) 2018-01-31
US9586896B2 (en) 2017-03-07

Similar Documents

Publication Publication Date Title
CN105073105B (zh) 具有改善的治疗指数的硝酰基供体
HK1251170A1 (en) Nitroxyl donors with improved therapeutic index
HK40017499A (en) Nitroxyl donors with improved therapeutic index
HK1216857B (en) Nitroxyl donors with improved therapeutic index

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20181002